Floatz logo

Trastuzumab Deruxtecan

Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8

National Cancer Institute (NCI)antibody_drug_conjugatePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 cohort.

Asset / SponsorPhaseRating
Letrozole
Mayo Clinic
Phase 2B
Temsirolimus
National Cancer Institute (NCI)
Phase 2B
Ribociclib
Mayo Clinic
Phase 2B
Mirvetuximab Soravtansine
Ohio State University Comprehensive Cancer Center
Phase 1CCC
Pembrolizumab
Mayo Clinic
Phase 1/2CCC

View all 22 →

Same molecule, other indications

Trastuzumab Deruxtecan is also rated in:

HER2-low Expressing Breast CancerDormant
BBB
Indicative ·
77 / 100
View asset →
breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →